The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma
Open accessAbstract
PURPOSE: In patients with diffuse low-grade glioma (LGG), the extent of surgical tumor resection (EOR) has a controversial role, in part because a randomized clinical trial with different levels of EOR is not feasible. METHODS: In a 20-year retrospective cohort of 392 patients with IDH-mutant grade 2 glioma, we analyzed the combined effects of volumetric EOR and molecular and clinical factors on overall survival (OS) and progression-free survival by recursive partitioning analysis. The OS results were validated in two external cohorts (n = 365). Propensity score analysis of the combined cohorts (n = 757) was used to mimic a randomized clinical trial with varying levels of EOR. RESULTS: Recursive partitioning analysis identified three survival risk groups. Median OS was shortest in two subsets of patients with astrocytoma: those with postoperative tumor volume (TV) > 4.6 mL and those with preoperative TV > 43.1 mL and postoperative TV ≤ 4.6 mL. Intermediate OS was seen in patients with astrocytoma who had chemotherapy with preoperative TV ≤ 43.1 mL and postoperative TV ≤ 4.6 mL in addition to oligodendroglioma patients with either preoperative TV > 43.1 mL and residual TV ≤ 4.6 mL or postoperative residual volume > 4.6 mL. Longest OS was seen in astrocytoma patients with preoperative TV ≤ 43.1 mL and postoperative TV ≤ 4.6 mL who received no chemotherapy and oligodendroglioma patients with preoperative TV ≤ 43.1 mL and postoperative TV ≤ 4.6 mL. EOR ≥ 75% improved survival outcomes, as shown by propensity score analysis. CONCLUSION: Across both subtypes of LGG, EOR beginning at 75% improves OS while beginning at 80% improves progression-free survival. Nonetheless, maximal resection with preservation of neurological function remains the treatment goal. Our findings have implications for surgical strategies for LGGs, particularly oligodendroglioma. [Media: see text]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148 · cited 6×
“6 mL and (2) patients with astrocytoma who had no chemotherapy with preoperative TV # 43.”
BackgroundMethodInfluentialEANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048 · cited 3×
“These tumors include astrocytoma IDH-mutant (astrocytomas) and oligodendroglioma IDH-mutant 1p19q codeleted (oligodendroglioma), both with distinct clinical trajectories.(1,3,4,6,7) Despite their relatively slow growth, low-grade gliomas (LGGs) are locally invasive and prone to malignant transformation.”
BackgroundMethodSelf-citationJakola, A. S., Myrmel, K. S., Kloster, R., Torp, S. H., Lindal, S., Unsgård, G., & Solheim, O. (2012) · JAMA · doi:10.1001/jama.2012.12807 · Cited by 641
Self-citationMcGirt, M. J., Chaichana, K. L., Attenello, F. J., Weingart, J. D., Than, K., Burger, P. C., Olivi, A., Brem, H., & Quinoñes-Hinojosa, A. (2008) · Neurosurgery · doi:10.1227/01.neu.0000325729.41085.73 · Cited by 533
Chaichana, K. L., McGirt, M. J., Laterra, J., Olivi, A., & Quiñones-Hinojosa, A. (2010) · Journal of Neurosurgery · doi:10.3171/2008.10.jns08608 · Cited by 192 · cited 1×
“Despite their relatively slow growth, low-grade gliomas (LGGs) are locally invasive and prone to malignant transformation.(8,9)”
Background
Cited by
Weller, M., Wen, P. Y., Chang, S. M., Dirven, L., Lim, M., Monje, M., & Reifenberger, G. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00516-y · Cited by 592
Self-citationPrimary brain tumours in adults
van den Bent, M. J., Geurts, M., French, P. J., Smits, M., Capper, D., Bromberg, J. E. C., & Chang, S. M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01054-1 · Cited by 419
Self-citationvan den Bent, M. J., French, P. J., Brat, D., Tonn, J. C., Touat, M., Ellingson, B. M., Young, R. J., Pallud, J., von Deimling, A., Sahm, F., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae107 · Cited by 88
“25,32 The role of supramaximal resection in IDH-mutant glioma remains controversial, due in part to the lack of a reliable method to quantify the extent of resection beyond the T2/FLAIR-hyperintense tumor borders.”
BackgroundMethodInfluentialMachine learning for cryosection pathology predicts the 2021 WHO classification of glioma
Nasrallah, M. P., Zhao, J., Tsai, C. C., Meredith, D., Marostica, E., Ligon, K. L., Golden, J. A., & Yu, K.-H. (2023) · Med · doi:10.1016/j.medj.2023.06.002 · Cited by 67
Long-term follow up of patients with WHO grade 2 oligodendroglioma
Carstam, L., Latini, F., Solheim, O., Bartek, J., Pedersen, L. K., Zetterling, M., Beniaminov, S., Sjåvik, K., Ryttlefors, M., Jensdottir, M., et al. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04368-6 · Cited by 31
Self-citation
Metadata
- Authors
- Hervey-Jumper, S. L., Zhang, Y., Phillips, J. J., Morshed, R. A., Young, J. S., McCoy, L., Lafontaine, M., Luks, T., Ammanuel, S., Kakaizada, S., Egladyous, A., Gogos, A., Villanueva-Meyer, J., Shai, A., Warrier, G., Rice, T., Crane, J., Wrensch, M., Wiencke, J. K., Daras, M., Oberheim Bush, N. A., Taylor, J. W., Butowski, N., Clarke, J., Chang, S., Chang, E., Aghi, M., Theodosopoulos, P., McDermott, M., Jakola, A. S., Kavouridis, V. K., Nawabi, N., Solheim, O., Smith, T., Berger, M. S., & Molinaro, A. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2023-04-10
- Volume
- 41
- Issue
- 11
- Pages
- 2029-2042
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4313544674
- Cited by
- 175
- References
- 6
- FWCI
- 24.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. https://app.cochat.ai/papers/10.1200/jco.21.02929
- The paper
- Hervey-Jumper, S. L., Zhang, Y., Phillips, J. J., Morshed, R. A., Young, J. S., McCoy, L., Lafontaine, M., Luks, T., Ammanuel, S., Kakaizada, S., Egladyous, A., Gogos, A., Villanueva-Meyer, J., Shai, A., Warrier, G., Rice, T., Crane, J., Wrensch, M., Wiencke, J. K., . . . Molinaro, A. M. (2023). Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.21.02929
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.